Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presenting a KHE with the following characteristics:~  1. Clinical features and histological findings consistent with progressive, non-resectable KHE associated with KMP.~ 2. Patients must be 0 - 18 years of age at the time of study entry.~ 3. Without functional impairment requiring treatment of corticosteroid.~* Organ function requirements:~  1 Adequate liver function:~ 1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and~ 2. ALT and AST less than or equal to 2.5 x upper limit normal (ULN) for age.~  2 Adequate renal function:~ 1. 0-5 years of age maximum serum creatinine (mg/dL) of 0.8~ 2. 6-10 years of age maximum serum creatinine (mg/dL) of 1.0~ 3. 11-15 years of age maximum serum creatinine (mg/dL) of 1.2~ 4. 16-18 years of age maximum serum creatinine (mg/dL) of 1.5~* Adequate bone marrow function: Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter.~* Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.~Exclusion Criteria:~* Allergy to sirolimus or other rapamycin analogues.~* Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization.~* Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected.~* Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration).~* Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus.~* Patients who have a history of malignancy.~* Patients with an inability to participate or to follow the study treatment and assessment plan.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: ACTIVE_COMPARATOR): Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
- Sirolimus plus prednisolone (Type: ACTIVE_COMPARATOR): Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).